Copyright
©2010 Baishideng. All rights reserved.
World J Stem Cells. Apr 26, 2010; 2(2): 34-38
Published online Apr 26, 2010. doi: 10.4252/wjsc.v2.i2.34
Published online Apr 26, 2010. doi: 10.4252/wjsc.v2.i2.34
Application of human umbilical cord blood-derived mesenchymal stem cells in disease models
Ju-Yeon Kim, Hong Bae Jeon, Yoon Sun Yang, Wonil Oh, Jong Wook Chang, Biomedical Research Institute, MEDIPOST Co., Ltd, Seoul 137-874, South Korea
Author contributions: Kim JY, Jeon HB, Yang YS, Oh W and Chang JW wrote this paper
Supported by A grant from the National R&D Program for Cancer Control, Ministry of Health, Welfare and Family affairs, 0820040, South Korea
Correspondence to: Jong Wook Chang, PhD, Biomedical Research Institute, MEDIPOST Co., Ltd, Seoul 137-874, South Korea. jwc@medi-post.co.kr
Telephone: +82-2-34656771 Fax: +82-2-4751991
Received: January 4, 2010
Revised: January 28, 2010
Accepted: February 4, 2010
Published online: April 26, 2010
Revised: January 28, 2010
Accepted: February 4, 2010
Published online: April 26, 2010
Abstract
Human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) are regarded as an alternative source of bone marrow-derived mesenchymal stem cells because collection of cord blood is less invasive than that of bone marrow. hUCB-MSCs have recently been studied for evaluation of their potential as a source of cell therapy. In this review, the general characteristics of hUCB-MSCs and their therapeutic effects on various diseases in vitro and in vivo will be discussed.